Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 5/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7093868 | 0.93 | TSHR (0.57) | CYP1A2CYP2C19SMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL17885932 | 0.92 | CYP1A2 (0.50) | CYP1A2CYP2C19SMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL12697311 | 0.89 | CYP1A2 (0.51) | CYP1A2CYP2C19SMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL15762675 | 0.87 | CYP1A2 (0.48) | CYP1A2CYP2C19SMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL9698379 | 0.85 | TSHR (0.51) | CYP1A2CYP2C19SMN1; SMN2TSHRCYP3A4 | |
| SCHEMBL17090762 | 0.85 | LMNA (0.57) | CYP1A2CYP2C19SMN1; SMN2TSHRCYP3A4 | |
| SCHEMBL12075084 | 0.84 | TSHR (0.50) | TSHRTDP1ALDH1A1HSD17B10LMNA | |
| SCHEMBL6766000 | 0.84 | LMNA (0.52) | SMN1; SMN2TSHRCYP3A4MAPK1TP53 | |
| SCHEMBL15728540 | 0.83 | L3MBTL1 (0.47) | CYP1A2CYP2C19SMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL17980842 | 0.82 | TSHR (0.53) | TSHRL3MBTL1TDP1CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299267-B2 | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating | COMENTIS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100286170-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC | 2010-11-11 | — | — | US | disclosed |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2009042694-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009015369-A2 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| US-20030144458-A1 | Novel amphiphilic polymeric materials | UNIVERSITY OF MASSACHUSETTS, A MASSACHUSETTS CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-6521736-B2 | Can be used in development of physiologically stable, non-leaking, non-immunogenic, efficacious and safe targetable drug delivery systems e.g., for delivery of anti-HIV or anticancer drugs | UNIVERSITY OF MASSACHUSETTS | 2003-02-18 | — | — | US | disclosed |
| US-20020099164-A1 | Novel amphiphilic polymeric materials | UNIVERSITY OF MASSACHUSETTS | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | BACE1, BACE2, APP | CYP1A2 2962/4885CYP2C19 4600/4885SMN1; SMN2 2575/4885 |
| US-20100286170-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | BACE1, BACE2, PSEN1 | CYP1A2 3830/4885CYP2C19 4622/4885SMN1; SMN2 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.